紫杉醇联合卡培他滨治疗Ⅳ期肺腺癌临床疗效及毒理研究

Clinical Efficacy and Toxicology of Paclitaxel Plus Capecitabine in the Treatment of Stage Ⅳ Adenocarcinoma of Lung

目的:探究紫杉醇联合卡培他滨方案治疗Ⅳ期肺腺癌的临床疗效及毒理研究。方法:选取我院肿瘤科收治的Ⅳ期肺腺癌患者62例,随机分为两组,其中对照组30例,给予卡培他滨口服常规治疗;实验组32例,在常规治疗的基础上加用紫杉醇治疗。对比两组有效率(RR)、疾病控制率(DCR)、中位进展时间(TTP)、中位生存期(MST)、血细胞分析情况、毒副作用发生率。结果:1实验组DCR高于对照组,差异具有统计学意义(P<0.05);2实验组TTP、MST明显优于对照组,结果有统计学意义(P<0.05);3两组患者血细胞各项指标无明显差异(P>0.05);两组患者脱发、肝损害、恶心呕吐的发生率无明显差异(P>0.05)。结论:紫杉醇联合卡培他滨方案可明显改善Ⅳ期肺腺癌患者的临床症状,延长患者的生存期,且毒副作用与单药治疗相比无差异,对临床具有指导意义,值得临床推广。

Objective： To explore the clinical efficacy and toxicology of paclitaxel plus capecitabine in the treatment of stage Ⅳadenocarcinoma of lung. Methods： 62 patients with stage Ⅳ adenocarcinoma of lung from the department of oncology of our hospital were selected and randomly divided into two groups, 30 patients in the control group treated with anti-emetic drugs symptomatic treatment, while another 30 patients in the experimental group treated by paclitaxel on the basis of conventional therapy. After the treatment, the efficiency rate（RR）, disease control rate（DCR）, the median time to progression（TTP）, the median survival time（MST）,blood cell analysis and the incidence of side effects was compared between two groups. Results： 1Compared with the control group, the DCR of experimental group was significantly higher（P〈0.05）; 2 the TTP and MST in the experimental group were significantly higher than that of the control group with statistically significant differences（P〈0.05）; 3there was no statistically significant difference in the blood cell analysis and the incidence of adverse reactions, such as the alopecia, liver damage, nausea and vomiting between two groups（P〉0.05）. Conclusions： Paclitaxel plus capecitabine can significantly improve the clinical symptoms of patients with stage Ⅳ lung adenocarcinoma, and prolong survival of patients, which might guide the treatment for clinic and be worthy of promotion.